Clinical trial · Interventional
Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)
Segmentectomy for Ground Glass-dominant Invasive Lung Cancer With Size of 2-3cm: a Single-arm, Multi-center, Phase III Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1012. The goal of this clinical trial is to confirm the theraputic effect of segmentectomy for ground glass-dominant invasive lung cancer with size of 2-3cm. The main questions it aims to answer are: * The 5-year disease-free survival of patients having ground glass-dominant invasive lung cancer with size of 2-3cm; * The post-operative lung function tests after receiving segmentectomy. Participants will receive segmentectomy as the surgical procedure.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Adenocarcinoma | Lung Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Segmentectomy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Segmentectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Segmentectomy
- description
- Segmentectomy is performed for ground glass-dominant invasive lung cancer with size of 2-3cm.
- interventionNames
- Procedure: Segmentectomy
Primary outcomes (1)
- measure
- 5-year disease-free survival
- timeFrame
- 5 years
- description
- The event is defined as the tumor recurrence or the death due to any causes.
Secondary outcomes (6)
- measure
- Lung function test
- timeFrame
- Half year and one year after surgical resection
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who sign the informed consent form and are willing to complete the study according to the plan; * Aged from 18 to 80 years old; * ECOG equals 0 or 1; * Not receiving lung cancer surgery before; * Confirmed to be invasive lung adenocarcinoma intraoperatively or postoperatively; * Ground glass-dominant lung nodules * Consolidation-to-tumor ratio (CTR) ranges from 0 to 0.5, and tumor size ranges from 2 to 3cm; * cN0 without distant metastasis; * Tumors could be completely resected assed by surgeons; * Not receiving chemotherapy or radiotherapy before. Exclusion Criteria: * CTR is not 0-0.5, or size is not 2-3cm; * Tumors could not be completely resected assed by surgeons; * Not lung adenocarcinoma diagnosed cytologically or pathologically; * Receiving lung cancer surgery before; * Receiving radiotherapy or chemotherapy.
References
Publications (1)
- DERIVEDChen S, Huang Q, Fu F, Wang Z, Zhang Y, Chen H. Segmentectomy for ground glass-dominant invasive lung cancer with tumour diameter of 2-3 cm: protocol for a single-arm, multicentre, phase III trial (ECTOP1012). BMJ Open. 2024 Jul 3;14(7):e087088. doi: 10.1136/bmjopen-2024-087088. PMID 38960464